Double Medical Technology Inc (002901) Fair Value & Analysis
Healthcare · CN · Market cap 17.4B CNY
Fair value as of: Jul 22, 2026
From 26 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from ¥31.33 to ¥30.74 (−1.9%) since Jun 25, 2026. Share price +1.0% over the past month.
A strong business, but screening 31% overvalued on our models.
What matters now
- A high-quality business (quality 85/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- A fairly wide model range (¥23.51 to ¥51.50) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥21.88 – ¥74.70 · fair‑value band ¥23.51 – ¥51.50 · the ¥44.55 price screens above the ¥30.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Double Medical Technology Inc (002901) currently trades at ¥44.55, while our model-based Fair Value estimate is ¥30.74, implying the stock looks roughly 31.0% overvalued today. The Quality Score stands at 85/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Double Medical Technology Inc generated revenue of 2.7B CNY at a net margin of 23.9%. Revenue grew 16.6% year over year. It earns a return on equity of 19.2%. The balance sheet holds a net cash position of 748M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥23.51 (bear case) to ¥51.50 (bull case); at ¥44.55, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 33% below its 52-week high and 27% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -31%, 002901 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥46.87) versus Asset-Based (¥5.78). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 82 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Double Medical Technology Inc. engages in the research, development, production, and sale of high-value medical consumables in China. The company offers orthopedic trauma implants, spinal implants, joint implants, sports medicine and neurosurgery implants, minimally invasive surgical implants, and dental implants. It also exports its products.
Full company description
Double Medical Technology Inc. engages in the research, development, production, and sale of high-value medical consumables in China. The company offers orthopedic trauma implants, spinal implants, joint implants, sports medicine and neurosurgery implants, minimally invasive surgical implants, and dental implants. It also exports its products. The company was formerly known as Xiamen Da Bo Ying Jing Medical Equipment Company Limited. Double Medical Technology Inc. was incorporated in 2004 and is headquartered in Xiamen, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Double Medical Technology Inc reported revenue of ¥2.6B in FY2025 versus ¥2.0B in FY2021, a compound +6.9%/yr. Reported net income was ¥600M in FY2025, compounding −2.9%/yr from FY2021.
002901 screens 31% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Double Medical Technology Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Double Medical Technology Inc (002901) overvalued or undervalued?
What is the fair value of 002901?
What is the quality score of 002901?
What is the revenue of Double Medical Technology Inc (002901)?
What is the net profit margin of 002901?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Double Medical Technology Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.